Orforglipron – complimentary MARA Rating report: pricing & reimbursement risk assessment for obesity and type 2 diabetes.
This complimentary MARA Rating® report reviews Orforglipron’s market-access profile for the treatment of obesity and type 2 diabetes. The therapy achieved a MARA Score of 2.3 out of 4, corresponding to a Marginal (B++) rating. Relative to benchmarks, the therapeutic area 5-year average is 2.8 and the overall industry average is 3.0, positioning Orforglipron notably below both.
Clinical Effectiveness: A+ (Very Strong)
Results from the pivotal _ACHIEVE-1_ Phase 3 trial demonstrated significant improvements in both glycemic control and weight reduction. At the highest dose, HbA1c was reduced by up to 1.6% and mean body weight by 7.3 kg compared to placebo plus standard care.
These findings indicate a clear efficacy advantage, though evidence beyond 40 weeks is not yet available, leaving long-term outcomes uncertain.
Comparator Selection: A+ (Very Strong)
Trials employed placebo and dulaglutide as comparators, which are clinically appropriate and relevant for the intended patient population. The use of an active comparator strengthens the robustness of the findings by allowing direct comparisons with established therapies.
Care-Pathway Integration: A+ (Very Strong)
Orforglipron can be integrated into current treatment pathways for diabetes and obesity without requiring new diagnostic tools or major care adjustments. Its oral formulation further simplifies administration and may support better patient adherence compared to injectable options.
About MARA Rating®
The MARA Rating synthesizes ten dimensions of market access risk – clinical efficacy, health-economic value, safety profile, comparator robustness, budget impact, and more – each scored on a seven-level scale (A++ to C).
We apply evidence-based weightings to generate a single risk score. A high MARA Score (A to A++) signals strong access prospects; a low score (B++ to C) denotes elevated pricing and reimbursement hurdles.
Unlock Premium Insights
Explore seven additional domains – Quality of Life (HRQoL), Cost-Effectiveness, Safety, Patient Population, Resource Use & Cost Implications, Evidence Quality, and Uncertainty – available exclusively in Premium Insights at mararating.com.
Full Premium Report available upon request: Visit mararating.com or email sales@mararating.com to learn more and unlock your access.
Access this report and hundreds of others: https://mararating.com/mara-ratings-list
Disclaimer: The MARA Rating® is an independent opinion of a drug’s market-access risk profile and is provided for informational purposes only – not as investment, medical, legal or any other type of advice. See our full disclaimer at mararating.com.